I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for treating pathologic ocular angiogenesis and any associated edema which comprises, administering a composition comprising an effective amount of a glucocorticoid and an effective amount of anecortave acetate.

2. (canceled)

3. (currently amended) The method of claim ~~2~~1, wherein the glucocorticoid is selected from the group consisting of triamcinolone acetonide, prednisolone, prednisolone acetate, rimexolone, fluoromethalone, and fluoromethalone acetate.

4. (currently amended) The method of claim ~~1~~3, wherein the glucocorticoid is triamcinolone acetonide.

5. (previously presented) The method of claim 4, wherein the concentration of triamcinolone in the composition is from 0.4% to 2.0% w/v.

6. (currently amended) The method of claim ~~1~~3, wherein the glucocorticoid is rimexolone.

7. (previously presented) The method of claim 6, wherein the concentration of rimexolone in the composition is from 0.1% to 4.0% w/v.

8. (currently amended) The method of claim ~~1~~3, wherein the glucocorticoid is prednisolone acetate.

9. (previously presented) The method of claim 8, wherein the concentration of prednisolone acetate in the composition is from 0.1% to 2.0% w/v.

10. (currently amended) The method of claim ~~1~~3, wherein the glucocorticoid is fluoromethalone acetate.

11. (previously presented) The method of claim 10, wherein the concentration of fluoromethalone acetate in the composition is from 0.1% to 1.0% w/v.

12. (previously presented) The method of claim 3, wherein the composition comprises anecortave acetate and triamcinolone acetonide.

13. (previously presented) The method of claim 12, wherein the concentration of anecortave acetate in the composition is from 0.1% to 6% w/v and the concentration of triamcinolone acetonide in the composition is from 0.5% to 4.0% w/v.

14. (previously presented) The method of claim 13, wherein the concentration of anecortave acetate in the composition is from 1% to 3% w/v.

15. (previously presented) The method of claim 14, wherein the concentration of anecortave acetate in the composition is 3% w/v.

16. (currently amended) The method of claim ~~2~~1, wherein the composition is delivered by intravitreal injection, ~~posterioir~~posterior juxtascleral delivery, subconjunctival injection, or via an implanted device.

17. (previously presented) The method of claim 16, wherein the composition is delivered by posterior juxtascleral injection.

18. (previously presented) The method of claim 16, wherein the composition is delivered via an implanted device.